U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Approval Year

2014
503
Substance Class Protein
Created
by admin
on Mon Mar 31 21:24:15 GMT 2025
Edited
by admin
on Mon Mar 31 21:24:15 GMT 2025
Protein Type MONOCLONAL ANTIBODY
Protein Sub Type IGG4
Sequence Origin HUMANIZED MOUSE
Sequence Type COMPLETE
Record UNII
DPT0O3T46P
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PEMBROLIZUMAB
DASH   INN   USAN   VANDF   WHO-DD  
USAN   INN  
Official Name English
pembrolizumab [INN]
Preferred Name English
PEMBROLIZUMAB [USAN]
Common Name English
PEMBROLIZUMAB [MI]
Common Name English
KEYTRUDA
Brand Name English
IMMUNOGLOBULIN G4, ANTI-(HUMAN PROTEIN PDCD1 (PROGRAMMED CELL DEATH 1)) (HUMAN-MUS MUSCULUS MONOCLONAL HEAVY CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL LIGHT CHAIN, DIMER
Common Name English
KEYLYNK-010 COMPONENT PEMBROLIZUMAB
Code English
SCH-900475
Code English
LAMBROLIZUMAB
Common Name English
PEMBROLIZUMAB [VANDF]
Common Name English
MK 7684A COMPONENT PEMBROLIZUMAB
Common Name English
PEMBROLIZUMAB [PURPLE BOOK CDER]
Common Name English
MK-3475
Code English
MK-1308A COMPONENT PEMBROLIZUMAB
Common Name English
Pembrolizumab [WHO-DD]
Common Name English
PEMBROLIZUMAB [JAN]
Common Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 705319
Created by admin on Mon Mar 31 21:24:15 GMT 2025 , Edited by admin on Mon Mar 31 21:24:15 GMT 2025
FDA ORPHAN DRUG 502415
Created by admin on Mon Mar 31 21:24:15 GMT 2025 , Edited by admin on Mon Mar 31 21:24:15 GMT 2025
FDA ORPHAN DRUG 570816
Created by admin on Mon Mar 31 21:24:15 GMT 2025 , Edited by admin on Mon Mar 31 21:24:15 GMT 2025
FDA ORPHAN DRUG 578717
Created by admin on Mon Mar 31 21:24:15 GMT 2025 , Edited by admin on Mon Mar 31 21:24:15 GMT 2025
FDA ORPHAN DRUG 576917
Created by admin on Mon Mar 31 21:24:15 GMT 2025 , Edited by admin on Mon Mar 31 21:24:15 GMT 2025
FDA ORPHAN DRUG 511715
Created by admin on Mon Mar 31 21:24:15 GMT 2025 , Edited by admin on Mon Mar 31 21:24:15 GMT 2025
FDA ORPHAN DRUG 548216
Created by admin on Mon Mar 31 21:24:15 GMT 2025 , Edited by admin on Mon Mar 31 21:24:15 GMT 2025
WHO-ATC L01XC18
Created by admin on Mon Mar 31 21:24:15 GMT 2025 , Edited by admin on Mon Mar 31 21:24:15 GMT 2025
FDA ORPHAN DRUG 481715
Created by admin on Mon Mar 31 21:24:15 GMT 2025 , Edited by admin on Mon Mar 31 21:24:15 GMT 2025
FDA ORPHAN DRUG 605417
Created by admin on Mon Mar 31 21:24:15 GMT 2025 , Edited by admin on Mon Mar 31 21:24:15 GMT 2025
FDA ORPHAN DRUG 495415
Created by admin on Mon Mar 31 21:24:15 GMT 2025 , Edited by admin on Mon Mar 31 21:24:15 GMT 2025
FDA ORPHAN DRUG 381012
Created by admin on Mon Mar 31 21:24:15 GMT 2025 , Edited by admin on Mon Mar 31 21:24:15 GMT 2025
FDA ORPHAN DRUG 513115
Created by admin on Mon Mar 31 21:24:15 GMT 2025 , Edited by admin on Mon Mar 31 21:24:15 GMT 2025
EMA ASSESSMENT REPORTS KEYTRUDA (AUTHORIZED: MELANOMA)
Created by admin on Mon Mar 31 21:24:15 GMT 2025 , Edited by admin on Mon Mar 31 21:24:15 GMT 2025
NDF-RT N0000191260
Created by admin on Mon Mar 31 21:24:15 GMT 2025 , Edited by admin on Mon Mar 31 21:24:15 GMT 2025
NCI_THESAURUS C128037
Created by admin on Mon Mar 31 21:24:15 GMT 2025 , Edited by admin on Mon Mar 31 21:24:15 GMT 2025
Code System Code Type Description
FDA UNII
DPT0O3T46P
Created by admin on Mon Mar 31 21:24:15 GMT 2025 , Edited by admin on Mon Mar 31 21:24:15 GMT 2025
PRIMARY
DRUG CENTRAL
4924
Created by admin on Mon Mar 31 21:24:15 GMT 2025 , Edited by admin on Mon Mar 31 21:24:15 GMT 2025
PRIMARY
NDF-RT
N0000191259
Created by admin on Mon Mar 31 21:24:15 GMT 2025 , Edited by admin on Mon Mar 31 21:24:15 GMT 2025
PRIMARY Programmed Death Receptor-1-directed Antibody Interactions [MoA]
DAILYMED
DPT0O3T46P
Created by admin on Mon Mar 31 21:24:15 GMT 2025 , Edited by admin on Mon Mar 31 21:24:15 GMT 2025
PRIMARY
MERCK INDEX
m11762
Created by admin on Mon Mar 31 21:24:15 GMT 2025 , Edited by admin on Mon Mar 31 21:24:15 GMT 2025
PRIMARY
DRUG BANK
DB09037
Created by admin on Mon Mar 31 21:24:15 GMT 2025 , Edited by admin on Mon Mar 31 21:24:15 GMT 2025
PRIMARY
CAS
1422183-02-5
Created by admin on Mon Mar 31 21:24:15 GMT 2025 , Edited by admin on Mon Mar 31 21:24:15 GMT 2025
SUPERSEDED
INN
9798
Created by admin on Mon Mar 31 21:24:15 GMT 2025 , Edited by admin on Mon Mar 31 21:24:15 GMT 2025
PRIMARY
LACTMED
Pembrolizumab
Created by admin on Mon Mar 31 21:24:15 GMT 2025 , Edited by admin on Mon Mar 31 21:24:15 GMT 2025
PRIMARY
SMS_ID
100000157957
Created by admin on Mon Mar 31 21:24:15 GMT 2025 , Edited by admin on Mon Mar 31 21:24:15 GMT 2025
PRIMARY
CAS
1374853-91-4
Created by admin on Mon Mar 31 21:24:15 GMT 2025 , Edited by admin on Mon Mar 31 21:24:15 GMT 2025
PRIMARY
RXCUI
1547545
Created by admin on Mon Mar 31 21:24:15 GMT 2025 , Edited by admin on Mon Mar 31 21:24:15 GMT 2025
PRIMARY RxNorm
IUPHAR
7499
Created by admin on Mon Mar 31 21:24:15 GMT 2025 , Edited by admin on Mon Mar 31 21:24:15 GMT 2025
PRIMARY
ChEMBL
CHEMBL2364654
Created by admin on Mon Mar 31 21:24:15 GMT 2025 , Edited by admin on Mon Mar 31 21:24:15 GMT 2025
PRIMARY
USAN
ZZ-165
Created by admin on Mon Mar 31 21:24:15 GMT 2025 , Edited by admin on Mon Mar 31 21:24:15 GMT 2025
PRIMARY
HSDB
8257
Created by admin on Mon Mar 31 21:24:15 GMT 2025 , Edited by admin on Mon Mar 31 21:24:15 GMT 2025
PRIMARY
WIKIPEDIA
Pembrolizumab
Created by admin on Mon Mar 31 21:24:15 GMT 2025 , Edited by admin on Mon Mar 31 21:24:15 GMT 2025
PRIMARY
ChEMBL
CHEMBL3137343
Created by admin on Mon Mar 31 21:24:15 GMT 2025 , Edited by admin on Mon Mar 31 21:24:15 GMT 2025
PRIMARY
EVMPD
SUB167136
Created by admin on Mon Mar 31 21:24:15 GMT 2025 , Edited by admin on Mon Mar 31 21:24:15 GMT 2025
PRIMARY
NCI_THESAURUS
C106432
Created by admin on Mon Mar 31 21:24:15 GMT 2025 , Edited by admin on Mon Mar 31 21:24:15 GMT 2025
PRIMARY
From To
1_22 1_96
2_22 2_96
3_23 3_92
4_23 4_92
1_134 3_218
2_134 4_218
3_138 3_198
4_138 4_198
1_147 1_203
2_147 2_203
1_226 2_226
1_229 2_229
1_261 1_321
2_261 2_321
1_367 1_425
2_367 2_425
Glycosylation Type MAMMALIAN
Glycosylation Link Type Site
N 1_297
N 2_297
Related Record Type Details
PEMBROLIZUMAB DESFERRIOXAMINE ZIRCONIUM ZR-89
LABELED -> NON-LABELED
PROGRAMMED CELL DEATH PROTEIN 1
TARGET -> INHIBITOR
Related Record Type Details
PEMBROLIZUMAB
ACTIVE MOIETY

Structural Modifications

Modification Type Location Site Location Type Residue Modified Extent Fragment Name Fragment Approval
AMINO_ACID_SUBSTITUTION [1_1] [2_1] N-TERMINUS PIDOLIC ACID SZB83O1W42
Name Property Type Amount Referenced Substance Defining Parameters References
MOL_WEIGHT:NUMBER(CALCULATED) CHEMICAL
Biological Half-life PHARMACOKINETIC
Molecular Formula CHEMICAL
Vdss PHARMACOKINETIC
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966